US Edition
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
Summary by The AI Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
China’s NMPA approves initiation of InnoCare’s trial of B7-H3 targeted ADC
The China NMPA's CDE has granted approval to the IND application of InnoCare Pharma to initiate the trial of ICP-B794.The post China’s NMPA approves initiation of InnoCare’s trial of B7-H3 targeted ADC appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
